AstraZeneca PLC said on Monday that it has signed a deal with Allergan PLC AGN, +0.05% worth up to $1.52 billion through its global biologics research and development unit.
The bio-pharmaceutical company said that under the deal, Allergan will have the global rights to an antibody for Crohn’s disease.
Allergan will pay upfront $250 million, but it may also make some payments to AstraZeneca worth up to $1.27 billion, depending on how good the sales of the antibody are, the company said.
By Olga Cotaga
Source: MarketWatch
Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.
Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.
Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.
